185 related articles for article (PubMed ID: 16224268)
1. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.
Hinrichs CS; Palmer DC; Rosenberg SA; Restifo NP
J Immunother; 2005; 28(6):517-24. PubMed ID: 16224268
[TBL] [Abstract][Full Text] [Related]
2. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
Palmer DC; Balasubramaniam S; Hanada K; Wrzesinski C; Yu Z; Farid S; Theoret MR; Hwang LN; Klebanoff CA; Gattinoni L; Goldstein AL; Yang JC; Restifo NP
J Immunol; 2004 Dec; 173(12):7209-16. PubMed ID: 15585842
[TBL] [Abstract][Full Text] [Related]
3. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
4. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
Klebanoff CA; Finkelstein SE; Surman DR; Lichtman MK; Gattinoni L; Theoret MR; Grewal N; Spiess PJ; Antony PA; Palmer DC; Tagaya Y; Rosenberg SA; Waldmann TA; Restifo NP
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1969-74. PubMed ID: 14762166
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.
Wang LX; Li R; Yang G; Lim M; O'Hara A; Chu Y; Fox BA; Restifo NP; Urba WJ; Hu HM
Cancer Res; 2005 Nov; 65(22):10569-77. PubMed ID: 16288050
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
Wrzesinski C; Paulos CM; Gattinoni L; Palmer DC; Kaiser A; Yu Z; Rosenberg SA; Restifo NP
J Clin Invest; 2007 Feb; 117(2):492-501. PubMed ID: 17273561
[TBL] [Abstract][Full Text] [Related]
8. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
9. Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.
Ng SSM; Nagy BA; Jensen SM; Hu X; Alicea C; Fox BA; Felber BK; Bergamaschi C; Pavlakis GN
Clin Cancer Res; 2017 Jun; 23(11):2817-2830. PubMed ID: 27986749
[No Abstract] [Full Text] [Related]
10. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
11. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.
Díaz-Montero CM; El Naggar S; Al Khami A; El Naggar R; Montero AJ; Cole DJ; Salem ML
Cancer Immunol Immunother; 2008 Apr; 57(4):563-72. PubMed ID: 17726606
[TBL] [Abstract][Full Text] [Related]
12. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP
J Immunol; 2005 Mar; 174(5):2591-601. PubMed ID: 15728465
[TBL] [Abstract][Full Text] [Related]
14. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
Church SE; Jensen SM; Antony PA; Restifo NP; Fox BA
Eur J Immunol; 2014 Jan; 44(1):69-79. PubMed ID: 24114780
[TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.
Yu Y; Cho HI; Wang D; Kaosaard K; Anasetti C; Celis E; Yu XZ
J Immunol; 2013 Feb; 190(4):1873-81. PubMed ID: 23315072
[TBL] [Abstract][Full Text] [Related]
17. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
Kerkar SP; Sanchez-Perez L; Yang S; Borman ZA; Muranski P; Ji Y; Chinnasamy D; Kaiser AD; Hinrichs CS; Klebanoff CA; Scott CD; Gattinoni L; Morgan RA; Rosenberg SA; Restifo NP
J Immunother; 2011 May; 34(4):343-52. PubMed ID: 21499127
[TBL] [Abstract][Full Text] [Related]
18. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
19. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).
Salem ML; Díaz-Montero CM; Al-Khami AA; El-Naggar SA; Naga O; Montero AJ; Khafagy A; Cole DJ
J Immunol; 2009 Feb; 182(4):2030-40. PubMed ID: 19201856
[TBL] [Abstract][Full Text] [Related]
20. Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.
Kosaka A; Ohkuri T; Ikeura M; Kohanbash G; Okada H
Biochem Biophys Res Commun; 2015 Mar; 458(3):549-554. PubMed ID: 25677619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
